Rezolve AI has spent the past two weeks in visible retreat from the extreme short-side stress of late June — yet with Q2 results three weeks away, the de-escalation is incomplete enough to matter.
The clearest change since the previous notes is how far the lending market has normalised. Availability has climbed to 61.6%, up from a near-total lock-out on June 12 when it hit just 0.07% — meaning virtually every share in the lending pool was out on loan. Borrow costs tell the same story in reverse: the cost to borrow ran above 200% APR through late June and into July 1, but has since dropped steadily to 31.3%, still elevated relative to the late-May baseline of roughly 15–18% but no longer in crisis territory. Short interest has followed the borrow costs down. The short position has fallen 24% over the past month, from a peak near 50 million shares to 34.8 million, now equivalent to 11.6% of free float. The weekly direction is still negative — shorts shed roughly 16% of their position in the latest week — suggesting the unwind is ongoing rather than complete. The ORTEX short score reinforces the direction of travel: it has eased from 84.8 on June 29 to 80.0, still elevated in absolute terms (ranking in the top percentile of the universe), but clearly off its peak.
Options positioning doesn't add much pressure in either direction. The put/call ratio at 0.29 is nearly at its 52-week high of 0.294, but the z-score of roughly 1.0 — barely one standard deviation above the 20-day average of 0.28 — keeps it in the "unremarkable" category. The narrow PCR range overall, with a 52-week low of 0.113 and a high of 0.294, suggests the options market here is structurally call-heavy; that has been the consistent backdrop throughout the squeeze episode. What options confirm is that hedging demand hasn't spiked in the way it did on names with genuine two-sided controversy.
The insider picture adds an interesting counterweight to the short-side narrative. The company's founder and CEO, Daniel Wagner, put roughly $3.25 million into the stock in early April at $4.00 per share — above the current price of $2.62, making those purchases currently underwater. A director added a further $266,000 in mid-May at $2.78. Net insider buying over the past 90 days totals 908,556 shares worth $3.5 million. That's a relatively small percentage of a company with a float of roughly 300 million shares, but the direction is consistent: insiders bought during weakness, not strength. BlackRock lifted its position by 2 million shares to 12 million (3.0% of shares) as of April 30, and State Street added nearly 1 million shares through May. Those additions confirm that institutional flows have not been uniformly negative even as shorts were crowded in.
The four most recent earnings events show a stock that can swing hard on catalysts. The April 8 print delivered an 11.8% single-day loss; the April 15 event produced a 5% gain the following day. The June 26 report was followed by a 3.2% rise on the day but a 9.9% gain over the subsequent five days — assisted materially by the $300M buyback announcement that arrived around the same time. The stock has since pulled back 7.7% on the week to $2.62, retracing a portion of the June 30 rally that took it to $3.15.
With short interest still at 11.6% of float, borrow costs still well above their pre-squeeze baseline, and Q2 results on July 30, the question heading into the next three weeks is whether the remaining short book continues to unwind gradually — or whether another catalyst forces the pace.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
